Sriram Ryali
Directeur Financier/CFO chez CODEXIS, INC.
Fortune : 170 769 $ au 30/04/2024
Profil
Sriram Ryali is currently the Chief Financial & Accounting Officer at Codexis, Inc. Prior to his current position, he held various roles including Senior Director-Financial Planning & Analysis at Jazz Pharmaceuticals Plc, Vice President-Finance at Aimmune Therapeutics, Inc., Chief Financial Officer at Eiger BioPharmaceuticals, Inc., and Head-Medical Affairs, Technical Operations, R&D at Onyx Pharmaceuticals, Inc. Mr. Ryali completed his undergraduate degree at the University of California, Los Angeles and holds an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CODEXIS, INC.
0,09% | 18/04/2024 | 64 441 ( 0,09% ) | 170 769 $ | 30/04/2024 |
Postes actifs de Sriram Ryali
| Sociétés | Poste | Début |
|---|---|---|
| CODEXIS, INC. | Directeur Financier/CFO | 23/01/2023 |
Anciens postes connus de Sriram Ryali
| Sociétés | Poste | Fin |
|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Directeur Financier/CFO | 20/01/2023 |
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2018 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Directeur Technique/Scientifique/R&D | 01/01/2015 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | - |
Formation de Sriram Ryali
| University of California, Los Angeles | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| CODEXIS, INC. | Process Industries |
| Entreprise privées | 2 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
